BACKGROUND Published appropriate use criteria (AUC) for Mohs micrographic surgery (MMS) for melanoma are based on consensus opinion.
B
ased on the consensus opinion of expert dermatologists from the American Academy of Dermatology, the American College of Mohs Surgery, the American Society for Dermatologic Surgery, and the American Society for Mohs Surgery, Mohs micrographic surgery (MMS) is considered to be appropriate for primary melanoma in situ and lentigo maligna located on the head and neck, acral sites, genitalia, and pretibial leg and for locally recurrent melanoma in situ or lentigo maligna in any location. The guidelines do not comment on invasive melanomas. 1 Appropriate use criteria (AUC) are useful if they identify melanomas that are at increased risk for suboptimal outcomes with conventional excision and that will benefit from superior outcomes by being treated with MMS.
Suboptimal outcomes after conventional excision may result when melanomas have indistinct clinical margins or reconstruction is performed before confirmation of clear margins. Melanomas with indistinct clinical margins are at increased risk for local recurrence or positive pathologic margins with conventional excision. 2, 3 If reconstruction is performed immediately after conventional excision and before confirming clear margins, patients may require additional excisions and more complex reconstruction procedures.
Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining addresses these practical challenges. 4 Complete peripheral and deep microscopic margin evaluation of the sections of the Mohs layers aided by immunostains assures local clearance of more than 99% of tumors and allows for immediate reconstruction in a reliably tumor-free skin. [4] [5] [6] [7] This retrospective study of a large cohort of both in situ and invasive melanomas treated with MMS evaluates the correlation between published AUC (anatomic location, recurrent status, and tumor stage) and the frequency of subclinical spread (a surrogate for indistinct clinical margins) or reconstruction with a flap or graft. These data may help to refine AUC and treatment guidelines for surgery of melanoma.
Methods

Experimental Design
Institutional review board approval was obtained before initiating this retrospective cohort study. Five hundred ninety-one consecutive primary or locally recurrent cutaneous melanomas without clinical evidence of in-transit, regional, or distant metastasis at the Data for all tumors had been prospectively entered at the time of MMS in an electronic database that includes the following: demographics, preoperative diagnosis and tumor stage (based on original biopsy), postoperative diagnosis and tumor stage (based on pathologic review of the entire tumor), tumor location, number of stages of MMS, and type of reconstruction. All data were verified by a search through the electronic and/or physical medical records. All diagnoses were verified by examination of the biopsy reports from both the preoperative diagnostic biopsy and from the formalin-fixed paraffin-embedded (FFPE) sections of the debulking excision or any other sections with invasive disease removed at the time of MMS. Only lesions with a definitive preoperative diagnosis of either in situ or invasive melanoma were included in this retrospective study. Melanocytic tumors were excluded if they had an indeterminate preoperative diagnosis, such as atypical intraepidermal melanocytic proliferation.
Surgical Procedure
All patients were treated under local anesthesia with a similar protocol, which has been previously described and illustrated. 4 A few key points merit emphasis. The clinically visible melanoma was first removed with a debulking excision, which was sent for FFPE breadloaf sections for purposes of tissue archiving and confirmation of pathologic staging. The Mohs layer was then excised for immediate complete peripheral and deep microscopic margin evaluation with frozen section hematoxylin and eosin stains and MART-1 immunostains. The peripheral margin of the Mohs excision was a minimum of 5 to 6 mm from the clinically visible edge of the melanoma for nearly all cases, and a 1-cm margin was excised whenever possible for melanomas with a tumor stage of T1b or greater.
The Mohs surgeon immediately reconstructed most wounds after confirming clear margin status. The few cases reconstructed by other surgical subspecialists were usually sent at the request of the referring surgical
subspecialist and did not necessarily represent increased complexity of the case.
Data Analysis
The following outcomes were assessed for each melanoma: presence of subclinical spread (defined as greater than 1 stage of MMS required to achieve tumor-free margins) and reconstruction with a flap or graft. Reconstruction data were unavailable for 10 cases, which were all located on the head and neck and were referred to outside physicians for repair. For these 10 cases, reconstruction was classified as not being performed with a flap or graft.
The frequency of subclinical spread or reconstruction with a flap or graft was correlated with anatomic location, recurrent status, and tumor stage. Anatomic location was classified as AUC-appropriate (head and neck, acral sites, genitalia, and pretibial leg) versus AUC-inappropriate (all other locations). Recurrent status was classified as primary (no previous treatment) versus recurrent (previously treated with surgical excision, laser, liquid nitrogen, cautery or curettage, chemical peels, or topical imiquimod). Tumor stage was classified as in situ versus invasive based on the most aggressive tumor noted on preoperative biopsy(ies). Odds ratios and 95% confidence intervals (CI) are reported. Fisher exact test was used to calculate a 2-tailed p-value, and a p < .05 was considered significant.
Results
The characteristics of 591 melanomas in 556 patients were analyzed. A total of 38.7% (229/591) were in female patients, and the mean age at the time of treatment was 65.6 years with a standard deviation of 13.1 years. A total of 512 (86.6%) cases were located in AUC-appropriate locations and 79 (13.4%) cases were located in AUC-inappropriate locations, 95% CI (83.9%-89.4%) and (10.6-16.1), respectively. A total of 101 (17.1%) lesions were recurrent ( 
Subclinical Spread
Subclinical spread was present in 32.5% (192/591) of tumors, 95% CI (28.7%-36.3%). Subclinical spread was statistically significantly more likely for melanomas that were in AUC-appropriate anatomic locations or that had recurred after previous treatment ( Table 2 ). The likelihood of subclinical spread was similar for in situ and invasive melanomas ( Table 2) .
Frequency of Reconstruction With a Flap or Graft
Flap or graft reconstruction was used in 47.9% (283/ 591) of tumors, 95% CI (43.9%-51.9%). Flap or graft reconstruction was statistically significantly more likely for melanomas that were in AUCappropriate anatomic locations or that had recurred after previous treatment ( Table 3 ). The frequency of reconstruction with a flap or graft was similar for in situ and invasive melanomas (Table 3) .
Discussion
This study demonstrates that current (Table 2) , supporting the use of MMS for lesions located on the head and neck, acral sites, genitalia, and pretibial leg and for recurrent melanomas in any anatomic location. The likelihood of subclinical spread was similar for in situ (31.6%) and invasive melanomas (35.3%), indicating that MMS is useful to detect and remove subclinical spread for both invasive and in situ melanomas (Table 2 ).
Melanomas requiring flap or graft reconstruction present a particular challenge for conventional surgery. If a positive margin is detected after performing flap or graft reconstruction, subsequent excision, pathologic margin assessment, and reconstruction are often more challenging. Anatomic location correlated strongly with the likelihood of reconstructing with a flap or graft. More than half (53.7%) of melanomas located on the head and neck, acral sites, genitalia, and 
pretibial leg required reconstruction with a flap and/or graft, compared with only 10.1% of melanomas located on the trunk and proximal extremities (p = .0001).
Compared with primary melanomas, recurrent lesions were statistically significantly more likely to require flap or graft reconstruction (Table 3) . A total of 17.1% of the melanomas in the authors' cohort had recurred after previous treatment. The authors' data suggest that these patients may have benefited from simpler reconstruction procedures of their primary melanomas. Patients place high value on restoring a normal appearance after reconstruction of facial defects, [13] [14] [15] so optimizing outcomes by confirming clear margins before reconstruction is especially important for melanomas in cosmetically or functionally sensitive locations. The incidence of flap or graft reconstruction did not vary between melanoma in situ (48.0%) and invasive melanoma (47.5%) (p = .9230).
The authors' study has limitations. Their clinic has a referral bias for large or ill-defined melanomas, and the frequency of melanomas in AUC-appropriate locations was higher than the frequency seen in the general population, 16 In summary, current AUC of anatomic location and recurrent status help to identify melanomas that have an increased risk for subclinical spread and that require flap or graft reconstruction. The risk of subclinical spread or reconstruction with a flap or graft does not differ for in situ or invasive melanoma, so consideration should be given to expand AUC to include invasive melanomas. Although AUC provide helpful guidelines, clinical judgment remains important to determine the utility of MMS for melanoma. For example, MMS may be useful for some poorly defined primary melanomas on the trunk and proximal extremities, as demonstrated by the fact that 21.5% (17/79) trunk and proximal extremity melanomas in this cohort had subclinical spread. However, conventional excision may be sufficient for welldemarcated, small melanomas of the head and neck. Future research will be useful to refine AUC and optimize triage of melanomas to MMS versus conventional excision. 
